
Record List Display Page 1 of 3

Generate Collection Print

Search Results - Record(s) 1 through 35 of 35 returned.

- 1. 20030055006. 25 Jun 01. 20 Mar 03. Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use. Siemeister, Gerhard, et al. 514/21; A61K038/18.
- 2. 20030008840. 07 May 02. 09 Jan 03. Methods for treating cancer. Vicari, Alain P., et al. 514/44; 424/144.1 424/178.1 424/93.2 A61K048/00 A61K039/395.
- □ 3. 20020197700. 30 Aug 01. 26 Dec 02. Receptor of the **EDb-fibronectin domains**. Menrad, Andreas, et al. 435/226; 435/320.1 435/325 435/69.1 435/7.23 536/23.2 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
- ☐ 4, 7335775, 25 Aug 06; 26 Feb 08. Effector conjugates, process for their production and their pharmaceutical use. Berger; Markus, et al. 546/268.1; 548/146 548/206 548/215 549/357. C07D277/20 20060101 C07D417/08 20060101.
- □ 5. WO2007128557A1, 26 Apr 07. 15 Nov 07. COMBINATION OF AN ANTI EDB FIBRONECTIN DOMAIN ANTIBODY L19-SIP AND AN ANTI-EGFR ANTIBODY. SIEGER, STEPHANIE, et al. C07K016/18:
- □ 6. EP001842553A1. 07 Apr 06. 10 Oct 07. Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule. MENRAD, ANDREAS DR, et al. CO7K016/18;
- T. WO2007054120AJ. 09 Nov 05. 18 May 07. IDENTIFICATION AND CHARACTERIZATION OF FUNCTION-BLOCKING ANTI-ED-B-FIBRONECTIN ANTIBODIES. MENRAD, ANDREAS, et al.
- □ 8. EP001663320A1. 01 Sep 04. 07 Jun 06. TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST <u>FIBRONECTIN ED-B</u>. BORSI, LAURA, et al. A61K051/10; A61P035/00.
- 9. <u>DE102004050101A1</u>. 14 Oct 04. 20 Apr 06. Recombined polypeptide antibody or antibody fragment binds the <u>ED-B domain of Fibronectin</u>. PRASSLER, JOSEF, et al. C07K016/18;.
- D 10. W02005023318A1. 01 Sep 04. 17 Mar 05. TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B. BORSI, LAURA, et al. A61K051/10: A61P035/00.
- 11. EP001514561A1. 10 Sep 03. 16 Mar 05. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B. A61K051/10:.
- ☐ 12. WO003076469A2. 11 Mar 03. 18 Sep 03. SELECTIVE TARGETING OF TUMOR VASCULATURE USING ANTIBODY MOLECULES. BORSI, LAURA, et al. C07K016/00;.
- ☐ 13. DE010123133A1. 02 May 01. 28 Nov 02. New proteins binding specifically to the ED-b fibronectin domain, are cell adhesion and proliferation mediators useful e.g. in screening tests.

Record List Display Page 2 of 3



Record List Display Page 3 of 3

pectoris. HELDMANN D.

27. WO 2005023318 A1. Specific binding component that binds human ED-B, labeled with isotope and comprising antigen-binding site that comprises antibody VH and VL domain, useful in manufacture of medicament for treating lesion of angiogenesis or tumor. BALZA E, et al.

28. EP [5]4561 AJ. New isotopically labeled specific binding member that binds human ED-B, useful for manufacturing a medicament for treating a lession of pathological angiogenesis, tumor, or for manufacturing a diagnostic reagent. BALZA E, et al.

29. WO 20055005985 Al. Device for direct, quantitative determination of analytes, useful for diagnosis, comprises immobilized specific binding agent, labeled analyte conjugate and immobilized binding agent for the label. LICHA K, et al.

30. EP 1462119 AJ. Producing pharmaceutical that modulates megalin-receptor mediated binding and/or uptake of radiodiagnostic and/or radiotherapeutic, in kidney cells of patients. BRAEUTIGAM M, et al.


31. WO 2004065491 A1. New indotricarbocyanine dyes are conjugated to biomolecules, used in fluorescence diagnosis of e.g. tumors. KAI L, et al.

32. WO 2004050089 A1. New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases. BOSSLET K, et al.

33. WO 03076469 A2. New specific binding member that binds human ED-B and comprises an antigen-binding site consisting of antibody VH and VL domains, useful for preparing a composition for treating tumors or a lesion of pathological angiogenesis. BAIZA E, et al.

34. DE 10104389 A1. New multimeric photosensitizer, useful in photodynamic therapy of cancers and other angiogenic conditions, can also be conjugated with e.g. protein, antibody or oligonucleotide. HACKBARTH S, et al.

35. WO 0220563 A2. New proteins binding specifically to the ED-b fibronectin domain, are cell adhesion and proliferation mediators useful e.g. in screening tests. BAHR I, et al.



Term	Documents
(21 NOT 19 NOT 14).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	35
(L21 not L19 not L14).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	35

Prev Page Next Page Go to Doc#